OpGen Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,410.60
4,126.40
3,157.70
4,025.70
3,211.00
2,946.30
Cost of Goods Sold (COGS) incl. D&A
2,773.50
951.70
1,547.60
2,289.90
2,133.20
1,848.40
Gross Income
362.90
3,174.60
1,610.10
1,735.80
1,077.80
1,097.90
SG&A Expense
9,967.50
8,739.30
16,143.00
20,745.10
16,464.60
14,278.10
EBIT
10,330.40
5,564.70
-
19,009.30
15,386.80
13,180.20
Unusual Expense
134.60
-
1,173.60
-
265.10
8.40
Non Operating Income/Expense
91.40
4.40
26.70
14.10
64.10
5.10
Interest Expense
31.60
111.30
1,801.30
143.30
233.50
191.20
Pretax Income
10,134.80
5,671.50
17,481.20
19,166.80
15,419.30
13,368.10
Income Tax
-
-
129.10
-
-
-
Consolidated Net Income
10,134.80
5,671.50
17,352.10
19,166.80
15,419.30
13,368.10
Net Income
10,134.80
5,671.50
17,352.10
19,166.80
15,419.30
13,368.10
Net Income After Extraordinaries
10,134.80
5,671.50
17,352.10
19,166.80
15,419.30
13,368.10
Net Income Available to Common
15,507.80
6,298.60
17,595.80
19,499.30
15,419.30
13,368.10
EPS (Basic)
36.17
14.69
55.00
27.50
9.80
2.22
Basic Shares Outstanding
428.80
428.80
319.20
706.70
1,573.80
6,009.10
EPS (Diluted)
36.17
14.69
55.12
27.59
9.80
2.22
Diluted Shares Outstanding
428.80
428.80
319.20
706.70
1,573.80
6,009.10
EBITDA
9,668.60
4,990.80
13,908.20
18,353.30
14,717.70
12,449.40
Non-Operating Interest Income
1.20
0.20
-
-
-
-
Preferred Dividends
5,373.00
627.10
243.80
332.60
-
-

About OpGen

View Profile
Address
708 Quince Orchard Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.opgen.com
Updated 07/08/2019
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.